JP2024520654A5 - - Google Patents

Info

Publication number
JP2024520654A5
JP2024520654A5 JP2023574412A JP2023574412A JP2024520654A5 JP 2024520654 A5 JP2024520654 A5 JP 2024520654A5 JP 2023574412 A JP2023574412 A JP 2023574412A JP 2023574412 A JP2023574412 A JP 2023574412A JP 2024520654 A5 JP2024520654 A5 JP 2024520654A5
Authority
JP
Japan
Prior art keywords
independently selected
cycloalkyl
alkyl
membered
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023574412A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520654A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/055131 external-priority patent/WO2022254362A1/en
Publication of JP2024520654A publication Critical patent/JP2024520654A/ja
Publication of JP2024520654A5 publication Critical patent/JP2024520654A5/ja
Pending legal-status Critical Current

Links

JP2023574412A 2021-06-03 2022-06-01 3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその医療用使用 Pending JP2024520654A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163196422P 2021-06-03 2021-06-03
US63/196,422 2021-06-03
PCT/IB2022/055131 WO2022254362A1 (en) 2021-06-03 2022-06-01 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and medical uses thereof

Publications (2)

Publication Number Publication Date
JP2024520654A JP2024520654A (ja) 2024-05-24
JP2024520654A5 true JP2024520654A5 (cg-RX-API-DMAC7.html) 2025-05-30

Family

ID=82115547

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023574412A Pending JP2024520654A (ja) 2021-06-03 2022-06-01 3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその医療用使用

Country Status (22)

Country Link
US (2) US12103919B2 (cg-RX-API-DMAC7.html)
EP (1) EP4347580A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024520654A (cg-RX-API-DMAC7.html)
KR (1) KR20240013812A (cg-RX-API-DMAC7.html)
CN (1) CN117062811A (cg-RX-API-DMAC7.html)
AR (1) AR126052A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022284366A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024905A2 (cg-RX-API-DMAC7.html)
CA (1) CA3215410A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003561A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024000013A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230614A (cg-RX-API-DMAC7.html)
DO (1) DOP2023000261A (cg-RX-API-DMAC7.html)
EC (1) ECSP24000004A (cg-RX-API-DMAC7.html)
IL (1) IL308094A (cg-RX-API-DMAC7.html)
JO (1) JOP20230308A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023014327A (cg-RX-API-DMAC7.html)
PE (1) PE20240657A1 (cg-RX-API-DMAC7.html)
PY (1) PY2243958A (cg-RX-API-DMAC7.html)
TW (1) TW202306570A (cg-RX-API-DMAC7.html)
UY (1) UY39796A (cg-RX-API-DMAC7.html)
WO (1) WO2022254362A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20250114A1 (es) 2021-06-03 2025-01-16 Chinook Therapeutics Inc Compuestos indol sustituidos y metodos de uso de los mismos
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
PL4245756T3 (pl) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
CN120129677A (zh) 2022-11-04 2025-06-10 百时美施贵宝公司 化合物及其用于治疗血红素病变的用途
TW202604526A (zh) * 2024-04-29 2026-02-01 美商必治妥美雅史谷比公司 化合物及其治療血色素病變之用途
CN118598797A (zh) * 2024-05-17 2024-09-06 诚达药业股份有限公司 一种手性3-羟基-4-氟哌啶衍生物的合成方法及拆分方法
WO2026002044A1 (zh) * 2024-06-25 2026-01-02 标新生物医药科技(上海)有限公司 含有硫/氧取代戊二酰亚胺基异吲哚啉酮骨架的双功能蛋白降解剂及它们的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
SG183257A1 (en) 2010-02-11 2012-09-27 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
WO2012068512A1 (en) 2010-11-18 2012-05-24 Deuteria Pharmaceuticals Llc 3-deutero-pomalidomide
WO2012079022A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
WO2014018866A1 (en) 2012-07-27 2014-01-30 Celgene Corporation Processes for preparing isoindoline-1,3-dione compounds
US20170038387A1 (en) 2015-08-04 2017-02-09 Celgene Corporation Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
WO2017185031A1 (en) 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
SI3526202T1 (sl) 2016-10-11 2025-04-30 Arvinas Operations, Inc. Spojine in postopki za ciljno razgradnjo androgenskih receptorjev
MX2019005007A (es) 2016-11-01 2019-07-18 Arvinas Inc Protac dirigidos a la proteína tau y métodos asociados de uso.
IL266842B (en) 2016-12-01 2022-09-01 Arvinas Operations Inc History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
CN110753693A (zh) 2016-12-23 2020-02-04 阿尔维纳斯运营股份有限公司 Egfr蛋白水解靶向嵌合分子和相关使用方法
IL325835A (en) 2016-12-23 2026-03-01 Univ Yale Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
US10806737B2 (en) 2016-12-23 2020-10-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
IL300417A (en) 2017-01-26 2023-04-01 Arvinas Operations Inc Bifunctional benzothiophene compounds, preparations containing them and their use in therapy
SG11202003415XA (en) 2017-10-18 2020-05-28 Novartis Ag Compositions and methods for selective protein degradation
EP3676268A1 (en) 2017-10-20 2020-07-08 Dana-Farber Cancer Institute, Inc. Heterobifunctional compounds with improved specificityfor the bromodomain of brd4
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2019177902A1 (en) 2018-03-10 2019-09-19 Yale University Modulators of btk proteolysis and methods of use
BR112020020307A2 (pt) 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
US12030892B2 (en) 2018-06-29 2024-07-09 Dana-Farber Cancer Institute, Inc. CRBN modulators
EP3814380A4 (en) 2018-06-29 2022-06-15 Dana Farber Cancer Institute, Inc. BISPECIFIC DEGRADATION PRODUCTS
AU2019294835B2 (en) 2018-06-29 2025-04-17 Dana-Farber Cancer Institute, Inc. Ligands to cereblon (CRBN)
CA3102212A1 (en) 2018-06-29 2020-01-02 Dana-Farber Cancer Institute, Inc. Immunomodulatory compounds
BR122022012697B1 (pt) * 2018-07-10 2023-04-04 Novartis Ag Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit
CN113490495B (zh) * 2018-12-03 2024-09-27 达纳-法伯癌症研究公司 Helios的小分子降解剂及其使用方法
JP7874541B2 (ja) 2019-09-16 2026-06-16 ノバルティス アーゲー 接着分解剤及びその使用方法
MX2022004526A (es) * 2019-10-17 2022-07-21 Arvinas Operations Inc Moléculas bifuncionales que contienen una porción de unión a la ligasa de ubiquitina e3 unida a una porción de direccionamiento a bcl6.
PH12022551482A1 (en) 2019-12-18 2023-11-29 Novartis Ag 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof

Similar Documents

Publication Publication Date Title
EP1027363B1 (en) Adenosine a1-receptor agonists
JP2024509981A5 (cg-RX-API-DMAC7.html)
RU2004106555A (ru) Производные фенэтаноламина для лечения респираторных заболеваний
RU2004138819A (ru) Ингибиторы протеинкиназ jak и cdk2
RU2004131641A (ru) Новые соединения
RU2005106846A (ru) Производные бензотиазола, характеризующиеся агонистической активностью к бета-2-адренорецепторам
RU2008142841A (ru) СОЕДИНЕНИЯ ИМИДАЗО-[1, 2-b]-ПИРИДАЗИНА (ВАРИАНТЫ), СПОСОБ ПОЛУЧЕНИЯ СОЕДИНЕНИЙ ИМИДАЗО-[1, 2-b]-ПИРИДАЗИНА (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ЛЕКАРСТВЕННОЕ СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ И/ИЛИ ПРЕДУПРЕЖДЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С МОДУЛЯЦИЕЙ ГАМКА РЕЦЕПТОРОВ
IL205501A (en) Preparation of preparations for the treatment of arthritis
JP2018109017A5 (cg-RX-API-DMAC7.html)
IL308094A (en) 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR MEDICAL USES
JP2019502686A5 (cg-RX-API-DMAC7.html)
RU2007106930A (ru) Производные хиназолина
RU98119076A (ru) Производные 2-(3h)-оксазолона и их применение в качестве ингибиторов сох-2
JP2005514370A5 (cg-RX-API-DMAC7.html)
JP2024509625A5 (cg-RX-API-DMAC7.html)
JP6184866B2 (ja) 新規抗がん剤
RU2004107847A (ru) Изоксазолпиридиноны и их применение в лечении болезни паркинсона
ZA200104269B (en) 4,5-azolo-oxindoles.
RU2004103079A (ru) Новые иммуномодулирующие соединения
RU2002105518A (ru) Гетероциклические соединения, ингибирующие ангиогенез
JP2007509052A5 (cg-RX-API-DMAC7.html)
EP3535239A1 (en) Inhibitors of mtor-deptor interactions and methods of use thereof
JP2006520396A5 (cg-RX-API-DMAC7.html)
JP5469707B2 (ja) 脳梗塞に関連する脳血管障害の治療に有用なピラゾロン化合物
RU2007128964A (ru) Антагонисты рецепторов 5-ht7